Want to see FR:GNFT full AI Analyst Report?
Top Page
Genfit
(GNFT)
Select Model
Select Model
Rating:52Neutral
Price Target:
€13.50
▲(47.06% Upside)
Action:Reiterated
Date:07/07/26
The score is held back primarily by weak and volatile financial performance, including a swing back to heavy losses, negative free cash flow, and a stressed balance sheet with negative equity. This is partially offset by strong technical momentum with the stock trading well above key moving averages, while valuation remains difficult to support due to negative earnings and no available dividend yield.
Positive Factors
Revenue rebound (2025)
A ~45% top-line rebound in 2025 indicates the company can materially grow sales, which supports long-term commercial viability. Sustained revenue recovery strengthens pricing leverage, partner negotiations and the potential to fund R&D or diagnostics rollouts without sole reliance on external capital.
Negative Factors
Balance-sheet stress / negative equity
The shift to negative shareholders' equity and higher debt materially reduces financial flexibility and increases insolvency risk. Over mid-term horizons this can raise funding costs, force dilutive financing or constrain strategic initiatives, limiting the company's ability to execute its clinical and commercial plans.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue rebound (2025)
A ~45% top-line rebound in 2025 indicates the company can materially grow sales, which supports long-term commercial viability. Sustained revenue recovery strengthens pricing leverage, partner negotiations and the potential to fund R&D or diagnostics rollouts without sole reliance on external capital.
Read all positive factors
Genfit (GNFT) vs. iShares MSCI France ETF (EWQ)
Market Cap
€685.56M
Dividend YieldN/A
Average Volume (3M)245.75K
Price to Earnings (P/E)―
Beta (1Y)1.44
Revenue Growth-2.34%
EPS Growth-5574.92%
CountryFR
Employees180
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.72
Shares Outstanding50,096,220
10 Day Avg. Volume239,968
30 Day Avg. Volume245,745
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-11.11
Price to Sales (P/S)4.01
P/FCF Ratio-9.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.3
Revenue Forecast (FY)€87.89M
Genfit Business Overview & Revenue Model
Company Description
Genfit S.A. operates as a biopharmaceutical enterprise, concentrating its efforts on discovering and developing both therapeutic candidates and diagnostic solutions for metabolic and liver-related ailments. Its current pipeline includes Elafibrano...
How the Company Makes Money
Genfit’s revenue model is primarily tied to (1) commercialization and sales of diagnostic products and related services, and (2) partnering activities typical of biopharmaceutical companies, such as licensing agreements and collaboration arrangeme...
Genfit Financial Statement Overview
Summary
Income Statement
44
Neutral
Balance Sheet
28
Negative
Cash Flow
35
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 65.43M | 67.00M | 28.57M | 20.20M | 80.07M |
| Gross Profit | 14.55M | 66.70M | 28.22M | 19.95M | 79.91M |
| EBITDA | -8.04M | 8.35M | -22.24M | -23.60M | 71.89M |
| Net Income | -85.97M | 1.51M | -28.89M | -23.72M | 67.26M |
Balance Sheet | |||||
| Total Assets | 157.93M | 151.42M | 173.87M | 215.54M | 281.72M |
| Cash, Cash Equivalents and Short-Term Investments | 101.09M | 81.79M | 77.79M | 140.55M | 258.76M |
| Total Debt | 150.69M | 62.13M | 70.18M | 75.28M | 74.23M |
| Total Liabilities | 181.58M | 82.20M | 105.92M | 121.01M | 162.62M |
| Stockholders Equity | -23.64M | 69.22M | 67.95M | 94.53M | 119.10M |
Cash Flow | |||||
| Free Cash Flow | -26.71M | 14.22M | -57.92M | -72.64M | 99.38M |
| Operating Cash Flow | -25.32M | 15.20M | -55.43M | -72.64M | 99.92M |
| Investing Cash Flow | -3.63M | -1.04M | 2.23M | -46.27M | -3.38M |
| Financing Cash Flow | 48.07M | -10.57M | -5.10M | -3.79M | -8.92M |
Genfit Technical Analysis
Positive
9.18
Price Trends
9.68
Positive
9.14
Positive
6.91
Positive
Market Momentum
1.18
Negative
77.84
Negative
87.58
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:GNFT, the sentiment is Positive. The current price of 9.18 is below the 20-day moving average (MA) of 11.26, below the 50-day MA of 9.68, and above the 200-day MA of 6.91, indicating a bullish trend. The MACD of 1.18 indicates Negative momentum. The RSI at 77.84 is Negative, neither overbought nor oversold. The STOCH value of 87.58 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:GNFT.
Genfit Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | €685.56M | -7.85 | -63.70% | ― | -2.34% | -5574.92% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | €10.71B | -24.87 | ― | ― | ― | ― | |
46 Neutral | €10.96M | -0.52 | ― | ― | ― | ― | |
45 Neutral | €881.16M | -1.97 | ― | ― | -51.26% | 17.63% | |
44 Neutral | €52.42M | -1.37 | ― | ― | 40.67% | 11.49% | |
43 Neutral | €28.07M | -1.62 | ― | ― | 417.14% | 22.08% |
* Healthcare Sector Average
FR:GNFT
Genfit
13.50
10.24
314.62%
FR:ABVX
Abivax SA
120.10
112.81
1547.46%
FR:IVA
Inventiva
3.75
1.02
37.18%
FR:POXEL
Poxel SA
0.20
-0.42
-68.12%
FR:ALVAL
Valbiotis SA
0.80
-0.01
-1.61%
FR:MAAT
MaaT Pharma
2.68
-1.95
-42.10%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.